Quanterix Corporation, based in Billerica, Massachusetts, is a life sciences enterprise dedicated to pioneering and commercializing advanced digital immunoassay platforms. These sophisticated systems are designed to enhance precision health in both scientific research and diagnostic applications, reaching markets across North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company's core offerings include several innovative instruments: The HD-X instrument, which provides highly sensitive and automated multiplex protein detection. The SR-X instrument, enabling researchers to leverage Simoa detection technology for diverse uses, such as the direct detection of nucleic acids. The SP-X instrument, which utilizes Simoa planar array technology for conducting multiplex chemiluminescent immunoassays. Alongside these platforms, Quanterix also supplies crucial consumables, including assay kits and reagents. In addition to its product line, the company delivers various contract research services, encompassing sample analysis, the development of custom "homebrew" assays, and other specialized research and development projects. Quanterix's operational focus spans critical health areas like neurology, oncology, cardiology, infectious diseases, and inflammation. Its clientele within the life science research sector primarily consists of laboratories affiliated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research organizations. Sales are managed through a multifaceted approach, combining a direct sales force, dedicated support organizations, and a network of distributors or sales agents. The company was initially incorporated in 2007 as Digital Genomics, Inc., before rebranding to Quanterix Corporation in August of the same year.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $135.44M | $121.14M | $105.52M | $110.56M | $86.38M | $56.73M | $37.63M | $22.87M |
| Cost of Revenue | $54.32M | $48.14M | $60.16M | $45.78M | $38.20M | $29.90M | $19.65M | $12.89M |
| Gross Profit | $81.12M | $73.00M | $45.36M | $64.77M | $48.18M | $26.84M | $17.98M | $9.99M |
| Gross Margin | 59.89% | 60.26% | 42.99% | 58.59% | 55.78% | 47.30% | 47.79% | 43.66% |
| Operating Expenses | $133.74M | $118.99M | $149.63M | $121.29M | $79.77M | $68.44M | $49.53M | $35.99M |
| Operating Income | $-52.62M | $-45.99M | $-104.26M | $-56.52M | $-31.58M | $-41.60M | $-31.55M | $-26.00M |
| Operating Margin | -38.85% | -37.97% | -98.81% | -51.12% | -36.57% | -73.32% | -83.84% | -113.69% |
| Net Income | $-38.53M | $-28.35M | $-99.57M | $-55.55M | $-31.53M | $-40.80M | $-31.05M | $-27.02M |
| Net Margin | -28.45% | -23.41% | -94.36% | -50.24% | -36.50% | -71.91% | -82.50% | -118.12% |
| EPS (Basic) | $-1.00 | $-0.86 | $-2.61 | $-1.60 | $-1.07 | $-1.63 | $-1.41 | $-1.24 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |